Cellectis
CLLS
#7233
Rank
โ‚ฌ0.41 B
Marketcap
3,97ย โ‚ฌ
Share price
-2.53%
Change (1 day)
113.95%
Change (1 year)

Revenue for Cellectis (CLLS)

Revenue in 2025 (TTM): โ‚ฌ66.22 Million

According to Cellectis's latest financial reports the company's current revenue (TTM ) is โ‚ฌ64.66 Million. In 2024 the company made a revenue of โ‚ฌ39.88 Million an increase over the revenue in the year 2023 that were of โ‚ฌ0.68 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Cellectis from 2015 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚ฌ66.22 M66.04%
2024 โ‚ฌ39.88 M5740.06%
2023 โ‚ฌ0.68 M-96.16%
2022 โ‚ฌ17.76 M-64.88%
2021 โ‚ฌ50.58 M-14.9%
2020 โ‚ฌ59.44 M340.73%
2019 โ‚ฌ13.48 M19.96%
2018 โ‚ฌ11.24 M-46.3%
2017 โ‚ฌ20.93 M-48.12%
2016 โ‚ฌ40.36 M-19.26%
2015 โ‚ฌ49.99 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
uniQure
QURE
โ‚ฌ13.53 M-79.07%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Novavax
NVAX
โ‚ฌ0.88 B 1,260.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
โ‚ฌ12.24 B 18,829.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Flexion Therapeutics
FLXN
โ‚ฌ86.25 M 33.39%๐Ÿ‡บ๐Ÿ‡ธ USA